My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are not the best or safest first option. Try appeals, manufacturer help, or an FDA‑approved alternative first. Compounded peptide products can be inconsistent, lack FDA testing, and carry contamination/dosing risks.

Why not compounded GLP‑1s

• Not FDA‑approved: potency, sterility and impurity testing aren’t guaranteed the way they are for brand drugs.
• Safety and legal concerns: the FDA and many clinicians warn against compounded versions of complex biologics (semaglutide, tirzepatide).
• Coverage and follow‑up: compounding pharmacies typically don’t offer the same support programs, dosing pens, or replacement/recall protections as the manufacturers.

What to try before considering compounding

1. Appeal the denial

   • Ask your prescriber to submit (or resubmit) a prior‑authorization with detailed clinical documentation: BMI, weight history, comorbidities (HTN, sleep apnea, diabetes, CVD risk), prior attempts at lifestyle/med therapy, and why Wegovy is medically necessary.
   • Request an internal appeal and, if denied, an external review (state regulator or independent review board). Insurers reverse many denials on appeal.

2. Manufacturer programs and discounts

   • Novo Nordisk NovoCare / Wegovy Savings Program — can substantially reduce out‑of‑pocket for commercially insured patients and has patient support resources. (Note: manufacturer coupons often can’t be used with Medicare/Medicaid.)
   • If you have Medicare or need financial assistance, check Novo Nordisk patient assistance or copay assistance eligibility and ask your provider to help enroll.

3. Try a different FDA‑approved GLP‑1 or covered alternative

   • Zepbound (tirzepatide) — Eli Lilly’s weight‑management product; some insurers cover it or cover tirzepatide (Mounjaro) for diabetes, which might be an access route.
   • Ozempic (semaglutide) or Mounjaro (tirzepatide) prescribed for type 2 diabetes — if you meet criteria, insulin/diabetes indications can make them covered.
   • Other FDA‑approved weight meds (Saxenda/liraglutide, Qsymia, Contrave, or surgery/behavioral programs) — ask which your plan covers.
   • Consider clinical trials — they can provide access to newer agents at no cost.

4. Use specialty pharmacies and clinician support

   • Many insurers require specialty pharmacy fills. Your prescriber’s office can help route the prior auth to the specialty pharmacy supported by the insurer to speed approval.

If you’re still considering compounded GLP‑1s

• Only consider as a last resort after exhausting appeals and alternatives, and only with full informed consent.
• If you proceed, choose an FDA‑registered 503B outsourcing facility (they follow more stringent testing and inspections than typical compounding pharmacies) and ask for:
  • Certificate of Analysis (COA) showing potency and sterility testing for the specific batch.
  • Evidence of sterility/ endotoxin testing and lot traceability.
  • Clear instructions and dosing devices compatible with the drug.
• Discuss potential legal, safety, and monitoring implications with your prescriber and get baseline labs and close follow‑up.

Practical next steps (recommended)

• Ask your prescriber to start an appeal / prior‑auth review now (include clinical notes).
• Call Novo Nordisk NovoCare (Wegovy support) to ask about savings programs and enrollment help.
• Ask your clinician whether an alternative FDA‑approved product (Ozempic, Mounjaro, Zepbound, Saxenda) is appropriate and if that route would be covered.
• If you want, tell me: your insurance type (commercial, Medicare, Medicaid) and whether your doctor will support an appeal — I can help draft appeal language or list specific program phone numbers and links.

If you want explicit help with an appeal letter or checking programs available for your insurance type, tell me your insurer and whether you have Medicare/Medicaid or commercial coverage.